Canaccord Genuity's 46th Annual Growth Conference
Logotype for Shoulder Innovations Inc

Shoulder Innovations (SI) Canaccord Genuity's 46th Annual Growth Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Shoulder Innovations Inc

Canaccord Genuity's 46th Annual Growth Conference summary

12 Aug, 2026

Market overview and growth drivers

  • Shoulder arthroplasty is a $2.8 billion global market, growing at over 10% annually, with a significant shift from inpatient to outpatient care, especially in ambulatory surgery centers following CMS reimbursement approval in January 2024.

  • The company targets 1,800 high-volume surgeons, representing 80% of procedures, enabling a focused and efficient commercial model.

  • Reverse shoulder replacements now account for 70% of procedures, reflecting evolving clinical practice and biomechanics.

  • The transition to ambulatory surgery centers is expected to drive substantial growth, with outpatient procedures rising from 10% to 30% by the end of 2025.

  • The company has achieved 60% revenue growth year-to-date, with gross margins in the upper 70% range and a strong cash position.

Product innovation and differentiation

  • The InSet Glenoid technology addresses glenoid component loosening, achieving 100% survivorship at 8.7 years and an 87% reduction in rocking horse motion.

  • Modular implant design allows intraoperative transition between anatomic and reverse procedures, enhancing surgical flexibility.

  • Instrument footprint is reduced to two trays, lowering costs and simplifying workflow in ambulatory settings.

  • Automated, AI-enabled, CT-based preoperative planning improves surgical accuracy and is being integrated with a portable robotic solution, with 510(k) filing planned for the first half of 2027.

  • New product launches include InSet 135 for fractures, N22 Glenosphere for metal sensitivity, TPS reverse baseplate, and a reusable guide system.

Commercial strategy and operational efficiency

  • The commercial model combines a 1099 independent sales force with over 40 W2 leaders and a Customer Experience in Medical Education (CEME) team, enabling targeted surgeon engagement and rapid growth.

  • Over 90 CEME events in the first half of the year engaged 160 practitioners, driving first-use adoption.

  • Cost-down initiatives and a low-inventory model support improved free cash flow and working capital efficiency, with cash burn reduced from $15M to $9M quarter-over-quarter.

  • The company is focused on expanding its core customer base, increasing average selling prices, and exploring adjacent markets and international expansion.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more